You are here:Home-Chemical Inhibitors & Agonists-Tyrosine Kinase-RET Tyrosine Kinase (c-RET)-Vepafestinib
Vepafestinib

Chemical Structure : Vepafestinib

CAS No.: 2129515-96-2

Vepafestinib (TAS0953, TAS-0953, HM06)

Catalog No.: PC-38426Not For Human Use, Lab Use Only.

Vepafestinib (TAS0953, HM06) is a next-generation RET inhibitor, potently inhibits recombinant WT RET kinase with IC50 of 0.33 nM, targets RET wild-type (WT) kinase and RET solvent front mutants (RETL730, RETV804 and RETG810).

Packing Price Stock Quantity
5 mg $258 In stock
10 mg $388 In stock
25 mg $598 In stock
100 mg Get quote

Bulk size, bulk discount!

E-mail: sales@probechem.com

Tech Support: tech@probechem.com

Purity & Documentation Purity: >98% (HPLC) Select Batch:

Biological Activity

Vepafestinib (TAS0953, HM06) is a next-generation RET inhibitor, potently inhibits recombinant WT RET kinase with IC50 of 0.33 nM, targets RET wild-type (WT) kinase and RET solvent front mutants (RETL730, RETV804 and RETG810).
Vepafestinib (TAS0953, HM06) displays excellent kinase selectivity against a panel of 255 recombinant kinases.
Vepafestinib (TAS0953, HM06) potently inhibits growth of Ba/F3 cells expressing KIF5B–RETWT or KIF5B–RET mutants (V804M, V804L, G810R, G810S, G810C), but not selpercatinib and pralsetinib.
Vepafestinib (TAS0953, HM06) suppresses phosphorylation of RETG810R, RETG810S and RETG810C with near-complete inhibition at 100 nM in Ba/F3 KIF5B–RETWT cells, but not selpercatinib and pralsetinib.
Vepafestinib (TAS0953, HM06) inhibits transmission of signals and blocks growth of cells with RET alterations, effectively inhibits cell growth of HBECp53-RET (CCDC6-RET fusion; IC50 = 60 nM), with little effect on the isogenic control HBECp53-EV cells.
Vepafestinib (TAS0953, HM06) modulates expression of cell cycle and apoptosis markers.
Vepafestinib (TAS0953, HM06) treatment (50 mg per kg BID and 100 mg per kg, once daily (QD)) caused significant reductions in ECLC5B xenograft tumor growth, shows anti-tumor activity against KIF5B–RETG810R-driven allograft tumors.
Vepafestinib (TAS0953, HM06) is more effective than selpercatinib at penetrating the brain and blocking intracranial tumor growth.

Physicochemical Properties

M.Wt 474.565
Formula C26H30N6O3
Appearance Solid
CAS No.
Storage
Solide Powder
-20°C 12 Months; 4°C 6 Months
In Solvent
-80°C 6 Months; -20°C 6 Months
Shipping
Solubility

10 mM in DMSO

Chemical Name/SMILES

4-amino-N-(4-(methoxymethyl)phenyl)-7-(1-methylcyclopropyl)-6-(3-morpholinoprop-1-yn-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide

References

1. Patent WO2017146116 A1.

Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright

Contact Us sales@probechem.com

Bulk Inquiry

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • *Additional Information:

Get Quote

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • Additional Information: